Atlas Trials

Xencor, Inc.

30 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Xencor, Inc.

RecordFirmDate
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors (NCT07593092)Xencor, Inc.2026-06-30
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases (NCT07284797)Xencor, Inc.2026-02-24
A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis (NCT07230353)Xencor, Inc.2025-10-21
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis (NCT06619990)Xencor, Inc.2024-10-10
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors (NCT06276491)Xencor, Inc.2024-04-04
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC (NCT06173505)Xencor, Inc.2023-12-27
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors (NCT05996445)Xencor, Inc.2023-07-28
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors (NCT05585034)Xencor, Inc.2022-12-14
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis (NCT06005792)Xencor, Inc.2022-10-10
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies (NCT05032040)Xencor, Inc.2022-07-21
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma (NCT05433142)Xencor, Inc.2022-06-13
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) (NCT05328102)Xencor, Inc.2022-04-15
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT05005728)Xencor, Inc.2021-10-22
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer (NCT04590781)Xencor, Inc.2021-05-10
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469)Xencor, Inc.2019-05-29
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (NCT03752398)Xencor, Inc.2019-05-01
Study Evaluating AMG 424 in Subjects With Multiple Myeloma (NCT03445663)Xencor, Inc.2018-07-31
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (NCT03517488)Xencor, Inc.2018-07-10
A Study of XmAb®18087 in Subjects With NET and GIST (NCT03411915)Xencor, Inc.2018-01-22

Track Xencor, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.